ESTRO 2022 - Abstract Book

S944

Abstract book

ESTRO 2022

For stage 3 patients, PS +/- adjuvant RT had a 1 year OS of 100% compared with primary chemoradiotherapy (CRT) (83.3%, CI 27.3-97.5) and RT alone (66.7%, 5.4-94.5). However, the 2 year OS rate for PS alone was 0%, whereas PS and adjuvant RT and CRT remained at 100% and 83.3% respectively. For stage 4a/b patients, the 2yr OS with PS and adjuvant RT, PS alone, CRT and RT alone was 100%, 50% (20.8-73.6), 0% and 53.3% (12.5-82.7) respectively. Palliative platinum-based chemotherapy had a 2 year OS of 40% (5.2-75.3). Of note, over 50% of patients received best supportive care (BSC). The most common site of recurrence was at the primary site. Initial treatment modality did not appear to affect this.

Conclusion Compared to other H&N SCC subsites, HPSCC continues to have poor outcomes. Our data supports the UK 1 year survival of 60%. A combination of advanced stage, poor fitness and age precluded many of our patients untreatable. A multimodality approach using combinations of surgery and radiotherapy appears to be advantageous. However, this needs to be balanced with the patient’s age and fitness, low long-term outcomes and the morbidity of multimodality treatment.

PO-1111 Hypoxia and Perfusion MR-Imaging on the MR-Linear Accelerator for Head and Neck Cancer

A. Gupta 1 , W. Bano 2 , H. Barnes 3 , K. Newbold 4 , C. Nutting 4 , S. Bhide 4 , K. Harrington 4 , A. Wetscherek 2 , K.H. Wong 4

1 Institute of Cancer Reseasrch, Radiotherapy and Imaging, London, United Kingdom; 2 Institute of Cancer Research, Radiotherapy and Imaging, London, United Kingdom; 3 The Royal Marsden Hospital, Therapeutic Radiography, London, United Kingdom; 4 The Royal Marsden Hospital, Head and Neck, London, United Kingdom Purpose or Objective The detrimental impact of hypoxia on tumour control has been well described in head and neck cancers (HNC). Tumour vasculature is morphologically abnormal, resulting in aberrant blood flow and oxygen delivery to cells. The Elekta Unity MR-linear accelerator (MRL) allows daily MR imaging and adaptive radiotherapy with the on-board 1.5T MRI scanner.